search
Back to results

A Study of DB-OTO, an AAV Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations (CHORD)

Primary Purpose

Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
DB-OTO
DB-OTO
Sponsored by
Decibel Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) focused on measuring DB-OTO, Gene Therapy, Congenital Hearing Loss, Sensorineural Hearing Loss, Auditory Neuropathy, Pediatric, Cochlear Implant, Otoferlin, Deaf, Hard of hearing, Hearing impaired, Hearing disorder, Fully implantable hearing aid, Child, Infant, CHORD

Eligibility Criteria

undefined - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Presence of pathogenic or likely pathogenic mutations in both alleles of the OTOF gene. Patient is of the appropriate age to qualify for enrollment in the corresponding age cohort at the time the parent/legal guardian signs the informed consent form For US and UK - Age of the patient - (infants to < 18 years of age at the time of the parent/legal guardian signing the informed consent form). Participant to provide assent, when applicable For Spain - 24 months of age or younger at the time of the parent/legal guardian signing the informed consent form Audiological Criteria: US: Investigator determines that minimal benefit has been provided by amplification of the ear to receive DB-OTO. Investigator determines the patient meets cochlear implantation criteria in both ears according to the recommended cochlear implant label Infants ≤24 months of age: Profound sensorineural hearing loss (SNHL; ≥ 90 dB HL) based on behavioral and physiologic measurements (ABR) of inner ear function. Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO Children >24 months to <18 years of age: Profound SNHL (≥ 90 dB HL) based on physiologic measurements (ABR) of inner ear function AND Behavioral open-set word recognition scores of < 30% in the ear that would receive DB-OTO Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO OR Presence of a cochlear microphonic in ears to receive DB-OTO. UK & Spain: Absence of an ABR neural signal in response to a click stimulus ≤85 dB nHL in the ear(s) to be injected with DB-OTO. Presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO Willingness of at least 1 parent/legal guardian to consent to vaccinations for the patient in accordance with the country-specific pediatric immunization schedule No clinically significant laboratory findings on clinical laboratory tests at time of Screening No evidence that hearing loss is dependent on body temperature (For US and UK only) - From study start and for the duration of the short-term follow-up period (18 months): Female patients of childbearing potential and fertile males, must agree to use highly effective contraception Female patients must agree not to become pregnant. Fertile male patients must agree not to father a child or donate sperm. Exclusion Criteria: History or presence of other permanent or untreatable hearing loss conditions. Prior or current cochlear implants in the ear(s) to be injected with DB-OTO History of risk factor(s) for auditory neuropathy not caused by OTOF mutations including: prematurity, low birth weight, hyperbilirubinemia, neonatal intensive care unit (NICU) admission, and/or low Apgar scores. Prior or current history of malignancies. Prior or current history of meningitis. History of prior treatment with gene therapy. Surgical anatomy that would preclude the planned surgical approach as indicated by medical imaging (eg, computed tomography [CT] or magnetic resonance imaging [MRI]) in the ear(s) to be injected with DB-OTO. Note: additional inclusion/exclusion criteria may apply, per protocol.

Sites / Locations

  • UCLA Health- Department of MedicineRecruiting
  • New York Presbyterian Hospital-Columbia University Medical CenterRecruiting
  • Seattle Children's Hospital dba Seattle Children's Research InstituteRecruiting
  • Hospital Universitario Insular Materno-Infantil de Las PalmasRecruiting
  • Hospital Universitario Ramón y CajalRecruiting
  • Clinica Universidad de NavarraRecruiting
  • Cambridge University Hospitals NHS Foundation TrustRecruiting
  • Great Ormond Street Hospital for Children- NHS Foundation TrustRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

DB-OTO - Dose Escalation

DB-OTO - Dose Expansion

Arm Description

Unilateral intracochlear dosing

Bilateral intracochlear dosing using the dose selected based on safety and efficacy data from the Dose Escalation phase (Part A).

Outcomes

Primary Outcome Measures

Incidence and severity of treatment-emergent systemic and local adverse events

Secondary Outcome Measures

Auditory brainstem response (ABR) - change in intensity threshold (decibels Hearing Level [dB nHL]) across frequency domains
Behavioral audiometry with pure-tone audiometry - change in intensity thresholds (dB HL) in treated ear across frequency domains, and speech awareness threshold (SAT) and speech reception threshold (SRT)- change in threshold in treated ear

Full Information

First Posted
March 15, 2023
Last Updated
October 11, 2023
Sponsor
Decibel Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT05788536
Brief Title
A Study of DB-OTO, an AAV Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
Acronym
CHORD
Official Title
A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 12, 2023 (Actual)
Primary Completion Date
August 19, 2030 (Anticipated)
Study Completion Date
August 19, 2030 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Decibel Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a first-in-human, multicenter, Phase 1/2, open-label, 2-part trial with a single-ascending dose patient cohort (Part A) and a bilateral expansion patient cohort (Part B) to evaluate the safety, tolerability, and preliminary efficacy of DB-OTO, an AAV based gene therapy in pediatric patients with biallelic OTOF mutations

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Keywords
DB-OTO, Gene Therapy, Congenital Hearing Loss, Sensorineural Hearing Loss, Auditory Neuropathy, Pediatric, Cochlear Implant, Otoferlin, Deaf, Hard of hearing, Hearing impaired, Hearing disorder, Fully implantable hearing aid, Child, Infant, CHORD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Model Description
DB-OTO will be administered as a single intracochlear injection into one (Part A) or both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
22 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
DB-OTO - Dose Escalation
Arm Type
Experimental
Arm Description
Unilateral intracochlear dosing
Arm Title
DB-OTO - Dose Expansion
Arm Type
Experimental
Arm Description
Bilateral intracochlear dosing using the dose selected based on safety and efficacy data from the Dose Escalation phase (Part A).
Intervention Type
Biological
Intervention Name(s)
DB-OTO
Intervention Description
DB-OTO will be administered as a single intracochlear injection into one ear (Part A). LD Cohort (starting dose) HD Cohort (high dose)
Intervention Type
Biological
Intervention Name(s)
DB-OTO
Intervention Description
DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.
Primary Outcome Measure Information:
Title
Incidence and severity of treatment-emergent systemic and local adverse events
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Auditory brainstem response (ABR) - change in intensity threshold (decibels Hearing Level [dB nHL]) across frequency domains
Time Frame
5 years
Title
Behavioral audiometry with pure-tone audiometry - change in intensity thresholds (dB HL) in treated ear across frequency domains, and speech awareness threshold (SAT) and speech reception threshold (SRT)- change in threshold in treated ear
Time Frame
5 years

10. Eligibility

Sex
All
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presence of pathogenic or likely pathogenic mutations in both alleles of the OTOF gene. Patient is of the appropriate age to qualify for enrollment in the corresponding age cohort at the time the parent/legal guardian signs the informed consent form For US and UK - Age of the patient - (infants to < 18 years of age at the time of the parent/legal guardian signing the informed consent form). Participant to provide assent, when applicable For Spain - 24 months of age or younger at the time of the parent/legal guardian signing the informed consent form Audiological Criteria: US: Investigator determines that minimal benefit has been provided by amplification of the ear to receive DB-OTO. Investigator determines the patient meets cochlear implantation criteria in both ears according to the recommended cochlear implant label Infants ≤24 months of age: Profound sensorineural hearing loss (SNHL; ≥ 90 dB HL) based on behavioral and physiologic measurements (ABR) of inner ear function. Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO Children >24 months to <18 years of age: Profound SNHL (≥ 90 dB HL) based on physiologic measurements (ABR) of inner ear function AND Behavioral open-set word recognition scores of < 30% in the ear that would receive DB-OTO Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO OR Presence of a cochlear microphonic in ears to receive DB-OTO. UK & Spain: Absence of an ABR neural signal in response to a click stimulus ≤85 dB nHL in the ear(s) to be injected with DB-OTO. Presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO Willingness of at least 1 parent/legal guardian to consent to vaccinations for the patient in accordance with the country-specific pediatric immunization schedule No clinically significant laboratory findings on clinical laboratory tests at time of Screening No evidence that hearing loss is dependent on body temperature (For US and UK only) - From study start and for the duration of the short-term follow-up period (18 months): Female patients of childbearing potential and fertile males, must agree to use highly effective contraception Female patients must agree not to become pregnant. Fertile male patients must agree not to father a child or donate sperm. Exclusion Criteria: History or presence of other permanent or untreatable hearing loss conditions. Prior or current cochlear implants in the ear(s) to be injected with DB-OTO History of risk factor(s) for auditory neuropathy not caused by OTOF mutations including: prematurity, low birth weight, hyperbilirubinemia, neonatal intensive care unit (NICU) admission, and/or low Apgar scores. Prior or current history of malignancies. Prior or current history of meningitis. History of prior treatment with gene therapy. Surgical anatomy that would preclude the planned surgical approach as indicated by medical imaging (eg, computed tomography [CT] or magnetic resonance imaging [MRI]) in the ear(s) to be injected with DB-OTO. Note: additional inclusion/exclusion criteria may apply, per protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Decibel Therapeutics, Inc.
Phone
+1-617-370-8701
Email
clinicaltrials@decibeltx.com
Facility Information:
Facility Name
UCLA Health- Department of Medicine
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Akira Ishiyama, MD
Email
aishiyama@mednet.ucla.edu
Facility Name
New York Presbyterian Hospital-Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lawrence R. Lustig, MD
Email
lrl2125@cumc.columbia.edu
Facility Name
Seattle Children's Hospital dba Seattle Children's Research Institute
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jay T. Rubinstein, M.D., Ph.D
Email
rubinj@uw.edu
Facility Name
Hospital Universitario Insular Materno-Infantil de Las Palmas
City
Las Palmas de Gran Canaria
ZIP/Postal Code
35016
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angel Ramos Macias, MD, PhD
Email
ramosorl@idecnet.com
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruben Polo López
Email
rubenpolo1979@gmail.com
Facility Name
Clinica Universidad de Navarra
City
Pamplona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manuel Jesus Manrique Rodriguez
Email
mmanrique@unav.es
Facility Name
Cambridge University Hospitals NHS Foundation Trust
City
Cambridge
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manohar Bance, FRCSC
Email
mlb59@cam.ac.uk
Facility Name
Great Ormond Street Hospital for Children- NHS Foundation Trust
City
London
ZIP/Postal Code
WC1N 3JH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Nash, FRCS
Email
r.nash@ucl.ac.uk

12. IPD Sharing Statement

Learn more about this trial

A Study of DB-OTO, an AAV Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

We'll reach out to this number within 24 hrs